Dana-Farber's Belfer Institute for Applied Cancer Science to Present at AACR Special Conference Molecular Targeted Therapies: Mechanisms of Resistance
Boston – May 3, 2012 - The Belfer Institute for Applied Cancer Science at Dana-FarberCancer Institute today announced that the Institute will co-chair and present at the upcoming Molecular Targeted Therapies: Mechanisms of Resistance, an American Association for Cancer Research (AACR) special conference, being held at The Westin San Diego from Wednesday, May 9 to Saturday, May 12, 2012.
Pasi Jänne, M.D., Ph.D., scientific director of the Belfer Institute for Applied Cancer Science at Dana-Farber, is a co-chair of the conference and will give a presentation titled “Strategies to overcome resistance to EGFR tyrosine kinase inhibitors,” during the EGFR session on Thursday, May 10, from 8 to 10 a.m.
About the Belfer Institute for Applied Cancer Science
The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute is a fully integrated, collaborative cancer research center offering innovative drug discovery capabilities that range from the identification of cancer-causing genetic mutations to the full validation and selection of new drug targets. This unique approach enables the Institute to focus on the most promising early-stage biology to define the best targets and the optimal clinical path for targeted cancer therapies. Collaborating closely with strategic partners in the pharmaceutical and biotechnology industry, the Institute’s proven team of leading scientists are translating key research findings into a revolutionary next generation of cancer therapies. The Belfer Institute was originally founded in 1999 and is part of Dana-Farber and affiliated with Harvard Medical School. For more information, please visit http://belferinstitute.dfci.harvard.edu/
In the News
Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".
Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.